

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

Listing of Claims:

Claims 1-23. (Canceled).

Claim 24. (Currently amended) A substantially pure or recombinant ~~antigenic~~ polypeptide comprising a sequence having at least 70% sequence identity with ~~of~~ SEQ ID NO:2.

Claim 25. (Currently amended) The polypeptide of Claim 24 comprising a sequence having at least 90% sequence identity with SEQ ID NO:2 ~~, wherein the polypeptide comprises:~~

- ~~—— a) residues 1-101 of SEQ ID NO:2;~~
- ~~—— b) residues 102-195 of SEQ ID NO:2;~~
- ~~—— c) residues 196-297 of SEQ ID NO:2;~~
- ~~—— d) residues 1-328 of SEQ ID NO:2; or~~
- ~~e) residues 1-606 of SEQ ID NO:2.~~

Claim 26. (Currently amended) A heterodimeric composition comprising the polypeptide of Claim 24 and human IL-12R β 1.

Claim 27. (Currently amended) The composition of Claim 26 capable of binding human IL-B30/p40.

Claim 28. (Previously presented) A kit comprising the polypeptide of Claim 24 and instructions for use.

Claim 29. (Currently amended) The kit of Claim 28, wherein the kit also contains:

- a) human IL-12R β 1 polypeptide;

b) human p40[[,]];:

c) human IL-B30[[,]]; or

d) human IL-B30/p40 polypeptides; ~~or~~

~~— e) an antibody having binding affinity for SEQ ID NO:2.~~

Claims 30-38. (Canceled).

Claim 39. (New) The polypeptide of Claim 24 comprising a sequence having fewer than 5 substitutions relative to the sequence of SEQ ID NO:2.

Claim 40. (New) The polypeptide of Claim 24 comprising a sequence having at least 95% sequence identity with SEQ ID NO:2.

Claim 41. (New) The polypeptide of Claim 24 comprising a sequence having at least 98% sequence identity with SEQ ID NO:2.

Claim 42. (New) The polypeptide of Claim 24, wherein the polypeptide, when combined with IL-12R β 1, is able to form a functional receptor complex for p40/IL-B30.

Claim 43. (New) The polypeptide of Claim 25, wherein the polypeptide, when combined with IL-12R β 1, is able to form a functional receptor complex for p40/IL-B30.

Claim 44. (New) The polypeptide of Claim 39, wherein the polypeptide, when combined with IL-12R β 1, is able to form a functional receptor complex for p40/IL-B30.

Claim 45. (New) The polypeptide of Claim 40, wherein the polypeptide, when combined with IL-12R β 1, is able to form a functional receptor complex for p40/IL-B30.

Claim 46. (New) The polypeptide of Claim 41, wherein the polypeptide, when combined with IL-12R β 1, is able to form a functional receptor complex for p40/IL-B30.